Recent Updates
Recently added Catalysts

Precision BioSciences, Inc.

DTILFDA catalysts, PDUFA dates & pipeline intelligence
$7.05
▼ -0.23 · -3.16%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full DTIL financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $3.5352W HIGH $11.29
Volume
350.99 K
Value Traded
2.48 M
Short % Float
8.68%
Days to Cover
10.5
-22.95%Week
+13.89%1 Month
-17.06%3 Month
-1.81%6 Month
-97.67%5 Year
-98.66%All Time

Cash Data

Unlock DTIL cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
269.10 M
EPS (TTM)
-1.01
P/E Ratio
-
Ent. Value
187.26 M
Total Shares
38.17 M
Float Shares
24.17 M
Insiders
13.49%
Institutions
67.71%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 1/2 data readout
PBGENE-DMD
Duchenne muscular dystrophy
Fast TrackOrphanRare Pediatric
Phase 1/2Gene TherapiesRare Disease
Unlock every DTIL catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

DTIL Catalyst Timeline

Dated clinical, regulatory and corporate events for Precision BioSciences, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Precision BioSciences, Inc.

443Total events
16Upcoming
85Tier-1 (high impact)
2019 to 2028Coverage

Upcoming catalysts 2

T2Timing Guidance
Subscribe to view catalyst details
PBGENE-HBV
T1Safety Data Update
Subscribe to view catalyst details
PBGENE-DMD

Event history 50

◆R&D DayPresentation
Investor and KOL webcast presenting late-breaking AASLD Phase 1 data
◆Late-BreakerPBGENE-HBVPresentation
Late-breaking oral presentation of Phase 1 ELIMINATE-B data at AASLD The Liver Meeting 2026
chronic hepatitis Bsource ↗
◆Timing GuidancePresentation
Expected closing of the $125 million offering
◆AbstractPBGENE-HBVPresentation
PBGENE-HBV late-breaking abstract data to become public ahead of AASLD presentation
chronic hepatitis Bsource ↗
▲DSMB ReviewPBGENE-DMDTrial
DSMB completes safety review of first PBGENE-DMD patient with no safety concerns and endorses dosing additional patients
Duchenne muscular dystrophysource ↗
▲Safety Data UpdatePBGENE-DMDClinical Data
First patient completes eight-week safety observation with no serious adverse events or AEs of special interest
Duchenne muscular dystrophysource ↗
▼Equity OfferingCorporate
Pricing of $125 million underwritten offering of common stock and pre-funded warrants
▲Safety Data UpdatePBGENE-HBVClinical Data
Phase 1 ELIMINATE-B data update: pgRNA loss, cccDNA reduction, HBsAg reductions, no DLTs
chronic hepatitis Bsource ↗
▲Dose Finding UpdatePBGENE-HBVTrial
0.4 mg/kg selected as go-forward Phase 2 dose for PBGENE-HBV
chronic hepatitis Bsource ↗
▲Trial InitiationPBGENE-HBVTrial
Initiation of global ELIMINATE-B2 Phase 2 study of PBGENE-HBV
chronic hepatitis Bsource ↗
Unlock the full DTIL catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How DTIL actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-11-08PBGENE-HBV Phase 1 data presentation Phase 1
Unlock 14 more DTIL historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 53%
Micro Cap
(rank 385 of 725)
Percentile Rank
Showing 3 of 4 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
PBGENE-DMD Gene TherapiesNCT07429240Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMDPhase 1/2 RECRUITING 18Dec 1, 2029
PBGENE-HBV Gene TherapiesNCT06680232HEPATITIS B CHRONICPhase 1 RECRUITING 45Jun 1, 2027
PBCAR19B Cell TherapiesCompletedNCT04649112CD19 Expressing MalignanciesPhase 1 COMPLETED 13Sep 30, 2023
Unlock the DTIL pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every DTIL program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
PBGENE-HBV
Fast Track
chronic hepatitis BPhase 12026-11-05100% pgRNA loss in evaluable patients at a 0.4 mg/kg dose; Durable and ongoing pgRNA loss in 100% of patients with ≥6 months of follow-up; 1-log and 1.5-log reduction in cccDNA at 0.4 mg/kg; Treatment effect observed in 100% of evaluable patients as measured by HBsAg reductionRead MorePrecision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting® 2026 Further Demonstrating cccDNA Elimination and Potential to Drive Viral CureRead More
Scroll for more · summaries link to the source press release
Unlock every DTIL trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock DTIL insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Scimeca DarioOfficer (Chief Legal Officer)Sell -2,821 56,782 held$9.75 11/10/2026
Unlock the full DTIL insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
PARKMAN HEALTHCARE PARTNERS LLC 0.5 % 5.24 M 836.76 K
Unlock every fund holding DTIL
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in DTIL
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see DTIL ownership
Insider and institutional ownership, quarter by quarter.

DTIL Short Interest

Shares sold short, counted twice a month.

8.68%
Short % of Float
of tradable shares sold short
2.1M
Shares Sold Short
-11.0% vs prior count
10.5 Very high
Days to Cover
trading days of normal volume to buy every short share back
199.4K
Avg Daily Volume
the average used for days to cover
Unlock DTIL short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock DTIL option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live DTIL option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock DTIL options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How DTIL ranks across every disease it competes in

Competitive Position is a premium feature
See how DTIL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

DTIL News

DTIL
Nov 5, 2026
DTILGeneral
▲ +21.6%on this news

Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Precision BioSciences announced a $125 million underwritten offering of common stock and pre-funded warrants. The offering includes 10,235,077 shares priced at $7.75 each and warrants for 5,893,964 shares. The funds will be used for ongoing research and development of gene editing therapies. The offering is expected to close on November 6, 2026.

Read more →
DTIL
Nov 5, 2026
DTILPhases
▲ +21.6%on this newsshared move

Precision BioSciences Announces Positive DSMB Safety Review Supporting Additional PBGENE-DMD Dosing in Phase 1/2 FUNCTION-DMD Study

Precision BioSciences announced that the independent Data Safety Monitoring Board (DSMB) has completed a safety review of PBGENE-DMD. The first patient treated showed no safety concerns, allowing for additional patient dosing in the Phase 1/2 FUNCTION-DMD study. This trial aims to evaluate the safety and efficacy of PBGENE-DMD for Duchenne muscular dystrophy.

Read more →
DTIL
Nov 5, 2026
DTILPhases
▲ +21.6%on this newsshared move

Precision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting® 2026 Further Demonstrating cccDNA Elimination and Potential to Drive Viral Cure

Precision BioSciences announced successful Phase 1 data for PBGENE-HBV, achieving 100% pgRNA loss in evaluable patients at a 0.4 mg/kg dose. The treatment demonstrated a well-characterized safety profile and significant reductions in cccDNA. The company plans to advance to a global Phase 2 study to evaluate cure rates in chronic hepatitis B patients.

Read more →
DTIL
Nov 3, 2026
DTILGeneral

Precision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business Update

Precision BioSciences reported its third quarter 2026 results, highlighting the dosing of the first patient in the FUNCTION-DMD study. The company also announced a late-breaking presentation for its PBGENE-HBV trial at the upcoming AASLD meeting. With a cash balance of $108 million, Precision expects to fund operations through 2028.

Read more →
DTIL
Oct 29, 2026
DTILGeneral

Precision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026

Precision BioSciences, Inc. will report its third quarter 2026 financial results on November 3, 2026. The company focuses on developing in vivo gene editing therapies using its proprietary ARCUS platform. This platform aims to provide defined therapeutic outcomes for various genetic and infectious diseases.

Read more →
DTIL
Oct 8, 2026
DTILConferences/Events

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026

Precision BioSciences has announced its selection for a late-breaking oral presentation at The Liver Meeting 2026. This prestigious event, organized by the American Association for the Study of Liver Diseases, will occur from November 5-9 in Denver. The presentation will focus on their PBGENE-HBV program, showcasing their ARCUS® gene editing technology.

Read more →
DTIL
Aug 24, 2026
DTILPhases

Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study

Precision BioSciences has initiated dosing in its Phase 1/2 FUNCTION-DMD clinical trial, focusing on PBGENE-DMD for Duchenne muscular dystrophy. This program aims to address a significant unmet medical need in the treatment of DMD. The trial marks a critical step in evaluating the efficacy of their gene editing therapy.

Read more →
DTIL
Aug 6, 2026
DTILGeneral

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Precision BioSciences reported its second quarter financial results for 2026, highlighting a significant milestone in the hepatitis B field with the first clinical biopsy evidence supporting its therapeutic approach. The company continues to advance its proprietary ARCUS platform for gene editing therapies targeting high unmet medical needs. Overall, the financial performance reflects positive growth and progress in its clinical initiatives.

Read more →
DTIL
Jul 31, 2026
DTILGeneral

Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026

Precision BioSciences, Inc. has announced it will report its financial results for the second quarter of 2026 on August 6, 2026. The company is focused on developing in vivo gene editing therapies using its proprietary ARCUS® platform. This announcement reflects the company's commitment to transparency and ongoing business operations.

Read more →
DTIL
Jul 27, 2026
DTILGeneral

Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones

Precision BioSciences has announced significant changes to its senior leadership team to enhance the advancement of its clinical programs. Alex Kelly has been promoted to Chief Operating Officer, a new role aimed at overseeing customer-facing functions. These changes are intended to support the company's strategic goals and address high unmet medical needs.

Read more →
DTIL
Jul 10, 2026
DTILGeneral

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Precision BioSciences has announced the approval of inducement awards for new employees under its 2021 Employment Inducement Incentive Award Plan. This decision, made by the Compensation Committee of the Board of Directors, reflects the company's commitment to attracting talent as it continues to develop its ARCUS platform for gene editing therapies.

Read more →
DTIL
Jun 29, 2026
DTILGeneral
▲ +8.6%on this news

Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors

Precision BioSciences has been included in the Russell 2000® Index, which is expected to enhance its market visibility and attract institutional investors. This inclusion reflects the company's growth and stability in the biopharma sector. The move is anticipated to bolster investor confidence and expand the company's reach.

Read more →
DTIL
May 27, 2026
DTILConferences/Events

Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026

Precision BioSciences has announced new and late-breaking clinical data from the PBGENE-HBV study during the European Association for the Study of the Liver Congress 2026. The details of the data and its implications for HBV treatment were highlighted, although specifics were not provided in the announcement.

Read more →
DTIL
May 21, 2026
DTILConferences/Events

Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026

Precision BioSciences is set to host an investor webcast to discuss the late-breaking data from the PBGENE-HBV trial presented at the European Association for the Study of the Liver Congress 2026. This event will provide insights into the findings and implications of the trial results for stakeholders. Further details about the webcast will be shared as the event approaches.

Read more →
DTIL
May 14, 2026
DTILConferences/Events

Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting

Precision BioSciences has presented new preclinical data for PBGENE-DMD at the American Society of Gene & Cell Therapy 2026 Annual Meeting. This advancement supports the transition of the therapy into clinical trials. The presentation highlights the company's ongoing commitment to developing innovative gene therapies.

Read more →
DTIL
May 5, 2026
DTILGeneral

Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update

Precision BioSciences has reported its financial results for the first quarter of 2026. The company also provided a business update, although specific details regarding performance or future plans were not disclosed in the article. The report appears to be standard for quarterly financial disclosures.

Read more →
DTIL
Apr 30, 2026
DTILGeneral

Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026

Precision BioSciences, Inc. has announced it will report its financial results for the first quarter of 2026 on May 5, 2026. The company is known for its proprietary ARCUS gene editing platform, which aims to develop therapies for genetic and infectious diseases. This announcement comes as the company continues to work on its clinical stage candidates.

Read more →
DTIL
Apr 29, 2026
DTILPhases

Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study

Precision BioSciences has activated the first clinical trial site for its PBGENE-DMD treatment aimed at Duchenne muscular dystrophy (DMD). The Phase 1/2 FUNCTION-DMD study will evaluate the safety, tolerability, and efficacy of this novel gene editing therapy. Patient enrollment has commenced at Arkansas Children's Hospital, which is recognized for its specialized care in DMD.

Read more →
DTIL
Apr 28, 2026
DTILConferences/Events

Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting

Precision BioSciences announced that new preclinical data from its PBGENE-DMD program will be presented at the ASGCT 2026 Annual Meeting. The data highlights the efficacy of PBGENE-DMD in early-juvenile mice, suggesting potential benefits for younger patients with Duchenne muscular dystrophy. The program aims to improve function in about 60% of DMD patients and has received FDA designations to expedite its development.

Read more →

About Precision BioSciences, Inc.

Durham, NC 69 employees precisionbiosciences.com
Headquarters302 EAST PETTIGREW STREET, DURHAM, NC, 27701
BIOPHARMAWATCH ELITE
Trade the next DTIL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime